Evommune, Inc.
NYSEEvommune enters the back half of August with a fresh analyst endorsement pulling in one direction and a short interest rebuild pulling in the other — a split signal that makes the stock genuinely interesting to watch right now. The most notable development this week is Needham's initiation of coverage with a Buy rating and a $28 price target, filed today. That sits alongside RBC…
EVMN cost to borrow doubles to 3.67%, up 106% in one week amid analyst downgrades and elevated short interest at 16.6% of float.
Snapshot as of 26 Aug 2026
Evommune enters the back half of August with a fresh analyst endorsement pulling in one direction and a short interest rebuild pulling in the other — a split signal that makes the stock genuinely interesting to watch…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for EVMN — free to start on ORTEX.
Sign up for free →Open EVMN on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live EVMN data →